Extended Data Table 2 |.
Antagonization of the antimicrobial activity of teixobactin by cell wall precursors
| a | ||||||||
|---|---|---|---|---|---|---|---|---|
| antagonist | C55-PP | C55-PP | C55-PP | lipid I | lipid II | lipid III | UDP-MurNAc-pentapeptide | UDP-GlcNAc |
| teixobactin | − | + | + | + | + | − | − | |
| vancomycin | − | − | nd | + | + | − | nd | nd |
| (+) antibiotic activity antagonized, (-) antibiotic activity unaffected, (nd) not determined | ||||||||
| b | |||||||
|---|---|---|---|---|---|---|---|
| lipid intermediate | molar ratio of precursor to teixobactin | ||||||
| Ox | 0.5 x | 1 X | 2.5 x | 5 x | 7.5 x | 10 x | |
| lipid II | − | + | + | + | + | + | + |
| C55-PP | − | − | − | − | + | + | + |
a,
S. aureus ATCC 29213 was incubated with teixobactin and vancomycin at 8 × MIC in nutrient broth in a microtitre plate, and growth was measured after a 24 h incubation at 37 °C. Putative HPLC-purified antagonists (undecaprenyl-phosphate [C55-P], farnesyl-pyrophosphate [C15-PP], undecaprenyl-pyrophosphate [C55-PP], UDP-MurNAc-pentapeptide, UDP-GlcNAc, lipid I, lipid II, and lipid III) were added in a fivefold molar excess with respect to the antibiotic. b, Teixobactin at 8 × MIC was exposed to increasing concentrations of putative antagonistic lipid intermediates. Experiments were performed with biological replicates.